Clinical Trials on AMH in New Zealand

Total 179 results

Pfenex, Inc

Completed

Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration

Age Related Macular Degeneration (AMD)

New Zealand
Reproductive Medicine Associates of New Jersey
Merck Sharp & Dohme LLC; Organon

Completed

Evaluation of Anti-mullerian Hormone Levels as Predictive of IVF Outcomes in Women Over 38 Years Old

AMH Levels | Inhibin B Levels | IVF Patients Over 38 Years Old

United States
Montefiore Medical Center

Recruiting

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

AML | MDS

United States
Eisai Inc.

Terminated

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Pediatric Acute Myelogenous Leukemia (AML)

United States, Canada, Australia
Institut de Recherches Internationales Servier
Celgene Corporation

Active, not recruiting

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS) | AML Arising From Antecedent Hematologic Disorder (AHD) | AML Arising After Exposure to Genotoxic Injury

United States, Germany, Netherlands
Actinium Pharmaceuticals

Recruiting

Venetoclax and Lintuzumab-Ac225 in AML Patients

Acute Myeloid Leukemia | Relapsed Adult AML

United States
Arog Pharmaceuticals, Inc.

Recruiting

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Newly Diagnosed FLT3 Mutated AML

United States
Rubius Therapeutics

Terminated

RTX-240 Monotherapy and in Combination With Pembrolizumab

Solid Tumor, AML Adult

United States
Georgetown University
National Heart, Lung, and Blood Institute (NHLBI); Jazz Pharmaceuticals

Recruiting

Phase IB/II of CPX-351 for Relapse Prevention in AML

Acute Myeloid Leukemia (AML) in Remission

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

Age-related Macular Degeneration (AMD)

United States
Seattle Children's Hospital
Children's Healthcare of Atlanta; Pediatric Oncology Experimental Therapeutics...

Completed

POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients

AML | Acute Leukemia of Ambiguous Lineage | ALL | Relapsed/Refractory AML | Relapsed/Refractory ALL | Secondary AML/MDS

United States, Canada
PTC Therapeutics

Terminated

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

Leukemia, Myeloid, Acute | AML

United States
VisionCare, Inc.

Enrolling by invitation

Post-Approval Study of the Implantable Miniature Telescope (PAS-01)

AMD

United States
Vitreous -Retina- Macula Consultants of New York

Completed

To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD

AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)

United States
Eisai Inc.

Withdrawn

A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Acute Myelogenous Leukemia (AML)

India
Cytheris, Inc.

Completed

Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant

AML | MDS | CML

United States
Biotronik AG

Completed

PROGRESS-AMS 1.0 Clinical Long Term Follow-Up

Long Term Safety of the AMS 1.0

Switzerland, Germany, Australia, Belgium, Netherlands
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

Age-related Macular Degeneration (AMD)

United States
Memorial Sloan Kettering Cancer Center

Terminated

Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors

Acute Myeloid Leukemia (AML)

United States
Kura Oncology, Inc.

Recruiting

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Neoplasms by Histologic Type | Acute Myeloid Leukemia | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | AML | Acute Leukemia | Hematologic Malignancy | NPM1 Mutation | AML With Mutated NPM1 | KMT2Ar | MLL Rearrangement

United States
AstraZeneca

Terminated

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Relapsed or Refractory Acute Myeloid Leukemia (AML)

United States
Therapeutic Advances in Childhood Leukemia Consortium
Bristol-Myers Squibb

Active, not recruiting

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

AML, Childhood

United States
Gemin X

Completed

Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)

AML

United States, Canada
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc.

Withdrawn

Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration (SEIRA)

Age Related Macular Degeneration | CNV | AMD

United States
Memorial Sloan Kettering Cancer Center
Astellas Pharma US, Inc.

Recruiting

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

United States
Weill Medical College of Cornell University

Terminated

Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML (Pacritinib)

Acute Myeloid Leukemia (AML)

United States
Synta Pharmaceuticals Corp.

Completed

STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

Myeloproliferative Disorders | AML | MDS | CML

United States
Bio-Path Holdings, Inc.

Recruiting

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Acute Myeloid Leukemia (AML)

United States
Celyad Oncology SA
IQVIA Biotech

Completed

DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 (DEPLETHINK)

AML | MDS

United States, Belgium
Tyrogenex
International Drug Development Institute; SynteractHCR

Terminated

X-82 to Treat Age-related Macular Degeneration

Eye Diseases | Macular Degeneration | Retinal Degeneration | Retinal Diseases | Age-Related Macular Degeneration (AMD) | Exudative Age-related Macular Degeneration | AMD | Macular Degeneration, Age-related, 10

United States
PureTech

Recruiting

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

MDS | AML, Adult Recurrent

United States
TScan Therapeutics, Inc.

Recruiting

A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation

Myelodysplastic Syndromes | AML | ALL, Adult

United States
Celularity Incorporated

Terminated

A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
Jazz Pharmaceuticals

Approved for marketing

EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML (401)

Secondary AML

United States
Celgene

Approved for marketing

Expanded Access for CC-486

Acute Myelogenous Leukemia (AML)

United States
Shire

Terminated

A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant

Acute Antibody-Mediated Rejection (AMR)

United States, Spain, France, Netherlands, Germany, Canada
Mana Therapeutics

Terminated

Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT

AML/MDS

United States
Maxinovel Pty., Ltd.

Recruiting

MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia (AML)

Australia
Daiichi Sankyo, Inc.

Completed

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

AML

United States, Korea, Republic of, Taiwan, United Kingdom, France, Australia, Spain, Italy, Canada, Singapore, Germany, Netherlands, Hong Kong, Belgium, Croatia, Czechia, Hungary, Poland, Serbia
AbbVie
Genentech, Inc.

Completed

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

AML | Acute Myelogenous Leukemia

United States, Australia, Germany, Italy
Genentech, Inc.

Completed

A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy

Leukemia, Myeloid, Acute

United States, Canada
AbbVie

Recruiting

Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

CNV | AMD | nAMD | Wet AMD | Wet Age-related Macular Degeneration | wAMD

United States
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

AML | MDS | CMML

United States, Canada
Celularity Incorporated

Recruiting

Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01)

Neoplasms | Neoplasms by Histologic Type | Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | Hematologic Neoplasms | Physiological Effects of Drugs | Peripheral Nervous System Agents | Analgesics | Analgesics, Non-narcotic | Antimetabolites, Antineoplastic | Leukemia in Remission | Relapsed... and other conditions

United States
NYU Langone Health

Completed

Rehabilitation in the Home Setting for Older Adults In the Early Period After Myocardial Infarction (RESILIENT)

Acute Myocardial Infarction (AMI)

United States
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Leukemia, Acute Myeloid (AML)

Japan, United States, Belgium, Canada, France, Germany, Israel, Italy, Korea, Republic of, Poland, Spain, Taiwan, Turkey, United Kingdom

Clinical Trials on AMH in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations